FDA Approves Mucinex 12HR Cold & Fever Multi-Symptom

The FDA approved Mucinex 12HR Cold & Fever Multi-Symptom, marking the first OTC innovation in the cold and flu category in 14 years. The product combines guaifenesin, dextromethorphan HBr, and naproxen sodium in a bilayer tablet designed to relieve fever, cough, chest congestion, and body pain for up to 12 hours per dose.¹

Mucinex 12HR Cold & Fever Multi-Symptom is now available at retailers nationwide.¹

"This approval is the culmination of more than a decade of research and development to create a first-of-its-kind formulation that delivers long-lasting relief from multiple cold and flu symptoms," Angela Naef, PhD, chief R&D officer at Reckitt, said in the news release.¹

A New Formulation for an Old Category

According to Reckitt, cold and flu symptoms are largely driven by the body's inflammatory response to infection. Mucinex 12HR Cold & Fever Multi-Symptom is the first product in its category to pair nonsteroidal anti-inflammatory drug (naproxen sodium) with guaifenesin, an expectorant, and dextromethorphan HBr, a cough suppressant, in a single bilayer tablet.¹

The formulation is built for immediate and extended release of its active ingredients, and the company said it delivers symptom relief that lasts up to 3 times longer than most cold and flu medicines when compared with 1 dose of a 4-hour medicine without redosing.¹

"By advancing the cold and flu category with longer-lasting, 12-hour symptom relief, we are not just expanding consumer choice and access, we are easing the care burden on families, and empowering people to stay focused on their daily lives," Jérôme Lemaire, president of Reckitt North America, said in a news release.¹

Mucinex 12HR Cold & Fever Multi-Symptom expands the broader Mucinex portfolio of 12-hour products, which Reckitt says consumers have trusted for more than 20 years to thin and loosen mucus, relieve chest congestion, and control coughing. The company noted the approval is the fourth for the Mucinex family of brands overall.¹

Why This Matters Now

The approval comes as influenza continues to place a substantial burden on the health care system. Reckitt cited CDC data showing the 2024-25 flu season resulted in an estimated 51 million illnesses, and the 2025-26 season saw a surge in cases nationwide that coincided with an earlier-than-usual start.¹

Separately, the CDC describes flu as a contagious respiratory illness that can cause fever, cough, sore throat, runny or stuffy nose, muscle or body aches, headaches, and fatigue, with symptoms that usually come on suddenly. The onset of symptoms typically occurs about 2 days after exposure, though it can range from 1 to 4 days, and people with flu are most contagious during the first 3 days of illness.²

The CDC notes that getting a flu vaccine has been shown to reduce the risk of flu and serious flu complications, though not everyone who contracts influenza develops a fever or other symptoms.²

The Mayo Clinic similarly notes that flu tends to come on quickly, within 2 to 3 days of exposure, and typically causes more severe symptoms than a common cold, including fever, cough, headache, muscle aches, fatigue, and chills.³

Most people recover from flu on their own within a week or 2, but Mayo Clinic cautions that certain populations—including adults older than 65 years, young children, and people with chronic conditions—are at higher risk of complications and should seek care promptly if symptoms appear, since starting antiviral medicine within 2 days of symptom onset may shorten the illness and help prevent more serious problems.³

Relevance for Pharmacists

As frontline, accessible health care providers, community pharmacists are often the first point of contact for patients navigating cold and flu symptoms, whether counseling on self-care or determining when a patient needs a higher level of intervention. A newly approved 12-hour multisymptom option adds to the self-care toolkit pharmacists can discuss with patients weighing OTC choices against convenience, dosing frequency, and symptom burden.

That counseling role increasingly overlaps with expanded clinical services. According to the National Alliance of State Pharmacy Associations (NASPA), pharmacist-based point-of-care test-and-treat services have transformed access to timely care, with pharmacists delivering testing and treatment for conditions including influenza, strep, and COVID-19 under temporary federal Public Readiness and Emergency Preparedness (PREP) Act authorities during the COVID-19 pandemic.²

NASPA states that this emergency flexibility demonstrated the profession's readiness to meet urgent health needs, improve patient outcomes, and reduce burdens on overtaxed health systems and that state pharmacy associations have continued advocating for expanded pharmacist prescribing authority, with new legislative wins each year granting pharmacists independent authority to test and treat for influenza and other conditions.²

As more states expand that authority, pharmacists are positioned not only to recommend products like Mucinex 12HR Cold & Fever Multi-Symptom but also, in a growing number of jurisdictions, to test for flu and initiate treatment directly.

REFERENCES

1. Reckitt announces U.S. FDA approval of Mucinex 12HR Cold & Fever Multi-Symptom, the first OTC innovation in the cold & flu category in 14 years. News release. Reckitt. August 5, 2026. Accessed August 5, 2026. https://www.reckitt.com/news/reckitt-announces-us-fda-approval-of-mucinex-12hr-cold-fever-multi-symptom-the-first-otc-innovation-in-the-cold-flu-category-in-14-years/

2. Centers for Disease Control and Prevention. About influenza. CDC. February 26, 2026. Accessed August 5, 2026. https://www.cdc.gov/flu/about/index.html

3. Mayo Clinic Staff. Influenza (flu) - symptoms and causes. Mayo Clinic. December 19, 2025. Accessed August 5, 2026. https://www.mayoclinic.org/diseases-conditions/flu/symptoms-causes/syc-20351719

4. National Alliance of State Pharmacy Associations. Pharmacist prescribing: test & treat. NASPA. Updated July 2026. Accessed August 5, 2026. https://naspa.us/resource/pharmacist-prescribing-for-strep-and-flu-test-and-treat/